Dr. Evans has been instrumental in the start-up and implementation of several major collaborative (industry/academia) research initiatives, including projects aimed at improving clinical assessments (Parkinson’s, Huntington’s disease, Major Depressive Disorder) and at predicting drug/placebo response. Dr. Evans has also been involved in a number of translational biomarker research projects, including the use of PET imaging to predict drug response and various proteomic and genomic biomarker discovery and development programs in diseases such as cancer and depression.